-
Tytuł:
-
Significance of digestive symptoms after COVID-19 vaccination: A retrospective single-center study.
-
Autorzy:
-
Lee DS; Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Internal Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Republic of Korea. Electronic address: .
Kim JW; Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: .
Lee KL; Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: .
Jung YJ; Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: .
Kang HW; Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: .
-
Źródło:
-
The American journal of emergency medicine [Am J Emerg Med] 2022 Aug; Vol. 58, pp. 154-158. Date of Electronic Publication: 2022 May 28.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 1983- : Philadelphia, PA : W B Saunders
Original Publication: [Philadelphia, PA. : Centrum Philadelphia, c1983]-
-
MeSH Terms:
-
COVID-19*/epidemiology
COVID-19*/prevention & control
COVID-19 Vaccines*/adverse effects
Digestive System Diseases*/etiology
Ad26COVS1 ; BNT162 Vaccine ; ChAdOx1 nCoV-19 ; Female ; Humans ; Male ; Retrospective Studies ; Vaccination
-
References:
-
Microbes Infect. 2020 Oct;22(9):481-488. (PMID: 32561409)
Lancet. 2020 Aug 15;396(10249):467-478. (PMID: 32702298)
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924. (PMID: 33332292)
Ann Neurol. 2021 May;89(5):856-857. (PMID: 33710649)
J Hepatol. 2020 Dec;73(6):1566-1568. (PMID: 32890595)
Ann Surg. 2020 Aug;272(2):e61-e62. (PMID: 32675498)
Am J Case Rep. 2020 Sep 24;21:e926785. (PMID: 32970653)
Pancreatology. 2020 Jul;20(5):1011-1012. (PMID: 32498972)
Ann Emerg Med. 1996 Mar;27(3):305-8. (PMID: 8599488)
Rev Soc Bras Med Trop. 2020 Nov 25;53:e20200714. (PMID: 33263693)
J Autoimmun. 2021 Aug;122:102685. (PMID: 34174723)
Medicine (Baltimore). 2021 Jan 29;100(4):e24369. (PMID: 33530232)
JAMA. 2021 Oct 12;326(14):1390-1399. (PMID: 34477808)
JAMA. 2020 Mar 17;323(11):1061-1069. (PMID: 32031570)
Sci Rep. 2021 Jul 30;11(1):15531. (PMID: 34330945)
N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013)
Clin Exp Dermatol. 2022 Jan;47(1):141-143. (PMID: 34236711)
Am J Kidney Dis. 2021 Jul;78(1):142-145. (PMID: 33839200)
N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609)
Int J Infect Dis. 2022 May;118:173-182. (PMID: 35276381)
J Clin Gastroenterol. 2022 Feb 1;56(2):e145-e148. (PMID: 33780223)
BMJ. 2021 May 5;373:n1114. (PMID: 33952445)
Crit Care. 2020 Jul 13;24(1):422. (PMID: 32660650)
JAMA. 2021 Mar 16;325(11):1101-1102. (PMID: 33576785)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
MMWR Morb Mortal Wkly Rep. 2020 Jun 19;69(24):759-765. (PMID: 32555134)
-
Contributed Indexing:
-
Keywords: Adverse reaction; COVID-19; Digestive symptoms; Vaccine
-
Substance Nomenclature:
-
JT2NS6183B (Ad26COVS1)
0 (COVID-19 Vaccines)
B5S3K2V0G8 (ChAdOx1 nCoV-19)
N38TVC63NU (BNT162 Vaccine)
-
Entry Date(s):
-
Date Created: 20220612 Date Completed: 20220719 Latest Revision: 20221221
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC9144838
-
DOI:
-
10.1016/j.ajem.2022.05.044
-
PMID:
-
35691237
-
Objective: There is insufficient research on digestive symptoms and outcomes following coronavirus disease (COVID-19) vaccination. We aimed to investigate digestive symptoms and related complications among South Koreans who were administered COVID-19 vaccines.
Methods: Forty-six patients (men: 22, women: 24) with a median age of 68 years (interquartile range:55.5, 73.8 years) who experienced digestive symptoms following COVID-19 vaccination between March 1 and July 30, 2021, were included. This retrospective single-center study collected information on clinical symptoms, laboratory tests, imaging results, comorbidities, complications, treatment type, and prognosis.
Results: Thirty-three (71.7%), nine (19.6%), and three (6.5%) patients were administered AZD1222 (AstraZeneca), BNT162b2 (Pfizer/BioNTech), and JNJ-78436735 (Johnson and Johnson) vaccines, respectively. Patients were classified with mild (25 patients, 54.3%), moderate (five patients, 10.9%), and severe (16 patients, 34.8%) based on disease severity. Digestive symptoms included abdominal pain, diarrhea, dyspepsia, and nausea, which usually developed within 1 day (78.3%) following the first vaccination. In total, 14 (30.4%) patients experienced only gastrointestinal symptoms, whereas 32 (69.6%) experienced non-gastrointestinal symptoms. Complications included enterocolitis (76%), acute kidney injury (9%), anaphylactoid reaction (2%), and duodenal perforation (2%).
Conclusions: COVID-19 vaccines caused digestive symptoms and other complications that ranged from mild to severe. While further validation is required, our results suggest that monitoring digestive symptoms following COVID-19 vaccination can help detect rather severe complications that require medical intervention.
Competing Interests: Declaration of Competing Interest None.
(Copyright © 2022. Published by Elsevier Inc.)
